Rigel Pharmaceuticals RIGL Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's pre-tax income?
- Rigel Pharmaceuticals (RIGL) reported pre-tax income of $11.66M in Q1 2026.
- How has Rigel Pharmaceuticals's pre-tax income changed year-over-year?
- Rigel Pharmaceuticals's pre-tax income increased by 1.3% year-over-year, from $11.51M to $11.66M.
- What is the long-term trend for Rigel Pharmaceuticals's pre-tax income?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's pre-tax income has grown at a 62.9% compound annual growth rate (CAGR), from -$17.31M to $121.83M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.